Quest Diagnostics Inc vs United Microelectronics Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while United Microelectronics Corp trades at $22.96 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 2.3× Quest Diagnostics Inc's market cap, and United Microelectronics Corp pays the higher dividend (1.76%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and United Microelectronics Corp for 42 Days on average.
| DGX | UMC | |
|---|---|---|
Market Cap | $25.48B | $58.02B |
Volume | 941,866 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $247.45 | $28.02 |
52-Week Low | $173.49 | $7.02 |
Typical Hold Time | 56 Days | 42 Days |
Enterprise Value | $31.23B | $55.10B |
Dividend Yield | 1.49% | 1.76% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
UMC trades at $22.82, down 2.1% over the past day, with a bullish technical signal but bearish moving averages. The company reported strong recent earnings beats, with Q2 2026 EPS of $0.54 versus $0.16 expected. Revenue for 2025 was $237.55B, with a net income margin of 16.99%. Analyst consensus is mixed, with 26.67% buy ratings and 53.33% hold. Recent news highlights AI-driven growth opportunities and a DCF intrinsic value estimate of $29.
The outlook for UMC is cautiously optimistic, driven by strong earnings performance and expanding AI opportunities. Key risks include competitive pressures in the semiconductor foundry space and potential volatility from AI spending fluctuations. The stock's current valuation metrics, including a P/E of 22.03, suggest room for growth if earnings trends continue.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →